ALS (Amyotrophic Lateral Sclerosis) Clinical Trial
— ALSOfficial title:
Cooperative Studies Program (CSP) #567 - A Clinical Demonstration of EEG Brain-computer Interface for ALS Patients
Verified date | January 2015 |
Source | VA Office of Research and Development |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Federal Government |
Study type | Observational |
The goal of this VA demonstration project is to show that the Brain-computer interface (BCI) technology is a clinically practical and important new communication and control option that can improve the lives of veterans with amyotrophic lateral sclerosis (ALS). The project will test four well-supported hypotheses: (1) that people with ALS who find (or will soon find) conventional assistive technology inadequate can and will use a BCI system for important purposes in their daily lives without close technical oversight, 2) they will continue and even increase this use throughout the period of the study, (3) that BCI use will improve their lives, and 4) BCI will improve the lives of their families and caregivers.
Status | Completed |
Enrollment | 27 |
Est. completion date | August 2014 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 79 Years |
Eligibility |
Inclusion and Exclusion Criteria 1. Subject will be a veteran with El Escorial "Lab Supported Probable" or more definite diagnosis of ALS. 2. Subject will have lost the ability to communicate either verbally or in writing (item 1 or item 4 on the ALS Functional Rating Scale-Revised (ALSFRS-R) score of 0, Appendix A) . 3. Subject will be an adult (age >18). 4. Subject will be living at home. 5. Subject will be living within 100 miles of the participating study site. 6. Subject will have corrected visual acuity of at least 20/80. 7. Subject will have the ability to read and understand 6th grade English text on a computer screen. 8. Subject will be able to indicate willingness and understanding of the consent form (using their existing method of communication). 9. Subject will be able to identify one significant other. 10. Subject will identify one system operator (person that agrees to be trained and set up the BCI). This person can be the significant other. 11. Subject will be able to communicate non-verbally with their significant other, caregiver and system operator, and with study personnel. 12. Significant other, caregiver and system operator will be able to indicate willingness and understanding of the consent form, be adults (age> 18) and expect to be with the subject for at least one year. 13. Subject, significant other, caregiver and system operator will have life expectancy of at least one year. 14. In the opinion of the BCI installation team, the home environment is physically and technologically conducive to BCI operation and use. 15. Subject will demonstrate during the screening phase sufficient EEG interaction for the BCI to operate, i.e. classification rate of 70%. Classification rate is defined as the proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters. 16. Significant other, caregiver and system operator will demonstrate during the screening phase sufficient skill to manage the daily set-up and routine operations needed for the subject's basic operation of the BCI. |
Observational Model: Cohort, Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
United States | Albany VA Medical Center Samuel S. Stratton, Albany, NY | Albany | New York |
United States | VA Medical Center, Cleveland | Cleveland | Ohio |
United States | Durham VA Medical Center, Durham, NC | Durham | North Carolina |
United States | Providence VA Medical Center, Providence, RI | Providence | Rhode Island |
United States | VA Connecticut Healthcare System West Haven Campus, West Haven, CT | West Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
VA Office of Research and Development | New York State Department of Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | BCI System Usage by the ALS Patient | This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by total time. | Up to 18 months | No |
Primary | BCI System Usage by the ALS Patient | This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by time per application. | Up to 18 months | No |
Primary | BCI System Usage by the ALS Patient | This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by accuracy. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g., THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The independent-use periods of the 14 independent users was totaled by days. Of these days, BCI use was not possible for days (i.e. hiatus days) due to hospitalization, illness, home construction, travel, or BCI system assistant (SA) absence. Over these days, copy-spelling accuracy was averaged. | Up to 18 months | No |
Primary | BCI System Usage by the ALS Patient | This study will look at the 14 independent users usage of the BCI system. The continued use will be assessed by selection rate. Accuracy rate - The proportion of correct selections made during the daily calibration period of "copy spelling." Copy spelling data refers to data collected while the patient attends to and selects specific predefined characters, this allows the data to be coded properly (e.g, THE QUICK BROWN FOX JUMPS OVER THE LAZY DOG). Copy spelling data is used for calibration and will be collected at least 2x/week, and may be collected more frequently if unstable performance could be improved by more frequent calibration runs. The number of selections/min for the BCI applications was averaged across users. | Up to 18 months | No |
Secondary | BCI Usage by and Impact on the ALS Patient | At three-month intervals, BCI use will be summarized. On a daily basis the BCI will record the total of number of selections made in copy spelling mode. Copy spelling mode is used for system calibration. Participants are expected to indicate that the burden associated with BCI use is inconsequential to the benefit derived from using the BCI. This will be assessed by the McGill Quality of Life (MQOL) at each visit. | Up to 18 months | No |
Secondary | Time of BCI Impact on the Significant Other and Systems Operator | The quality of life of the significant other, caregiver and system operator will be measured using the Caregiver Burden Assessment at visits. At three month intervals, the significant other, caregiver and system operator will be asked to estimate how much time they spend on the following tasks per day in minutes: BCI System setup ( placing the electrode cap and initiating system operation), BCI System cleanup, and BCI System maintenance (removing cap). | Up to 18 months | No |
Secondary | Facility Support Speed of Solution | This study will look at how the technical problems of the BCI are supported by the facility through analyzing the speed of solution. | Up to 18 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02528071 -
Prognostic Value of a Diaphragmatic Endurance Test in Patients With Amyotrophic Lateral Sclerosis
|
||
Active, not recruiting |
NCT03604822 -
Music Therapy Protocol to Support Bulbar and Respiratory Functions in ALS
|
N/A | |
Completed |
NCT02891629 -
Safety and Feasibility of the EyeControl Device
|
N/A | |
Completed |
NCT02164253 -
Focal Accumulation of Iron in Cerebral Regions in Early ALS (Amyotrophic Lateral Sclerosis) Patients
|
Phase 2 | |
Recruiting |
NCT03787420 -
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.
|
N/A | |
Recruiting |
NCT05663008 -
Impairments of Neuro-muscular Communication in Motor-Neuron Disease: A Bio-Marker for Early and Personalised Diagnosis
|
||
Active, not recruiting |
NCT02286011 -
Intramuscular Infusion of Autologous Bone Marrow Stem Cells in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Recruiting |
NCT03330353 -
Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy
|
N/A | |
Active, not recruiting |
NCT03081338 -
A Programme for Amyotrophic Lateral Sclerosis Care in Europe
|
N/A | |
Active, not recruiting |
NCT03241784 -
T-Regulatory Cells in Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Not yet recruiting |
NCT04849065 -
Clinical Trial on the Use of Cell Therapy in the Treatment of Patients With Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05276349 -
Home-based Remote Digital Monitoring to Assess ALS Progression (Track ALS)
|
||
Completed |
NCT04090684 -
Ciprofloxacin/Celecoxib Combination in Patients With ALS
|
Phase 1 | |
Active, not recruiting |
NCT04055623 -
T-regulatory Cells in ALS
|
Phase 2 | |
Completed |
NCT02709330 -
ALS Reversals - Lunasin Regimen
|
Phase 2 | |
Completed |
NCT03482050 -
A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1/Phase 2 |